These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

559 related items for PubMed ID: 29880491

  • 1. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.
    Chan DC, Watts GF, Somaratne R, Wasserman SM, Scott R, Barrett PHR.
    Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1644-1655. PubMed ID: 29880491
    [Abstract] [Full Text] [Related]

  • 2. Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes.
    Taskinen MR, Björnson E, Kahri J, Söderlund S, Matikainen N, Porthan K, Ainola M, Hakkarainen A, Lundbom N, Fermanelli V, Fuchs J, Thorsell A, Kronenberg F, Andersson L, Adiels M, Packard CJ, Borén J.
    Arterioscler Thromb Vasc Biol; 2021 Feb; 41(2):962-975. PubMed ID: 33356392
    [Abstract] [Full Text] [Related]

  • 3. Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism.
    Watts GF, Chan DC, Dent R, Somaratne R, Wasserman SM, Scott R, Burrows S, R Barrett PH.
    Circulation; 2017 Jan 24; 135(4):338-351. PubMed ID: 27941065
    [Abstract] [Full Text] [Related]

  • 4. Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state.
    Chan DC, Wong AT, Pang J, Barrett PH, Watts GF.
    Clin Sci (Lond); 2015 Mar 24; 128(6):379-85. PubMed ID: 25291660
    [Abstract] [Full Text] [Related]

  • 5. Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects.
    Taskinen MR, Björnson E, Andersson L, Kahri J, Porthan K, Matikainen N, Söderlund S, Pietiläinen K, Hakkarainen A, Lundbom N, Nilsson R, Ståhlman M, Adiels M, Parini P, Packard C, Borén J.
    J Clin Lipidol; 2020 Mar 24; 14(1):77-87. PubMed ID: 31917184
    [Abstract] [Full Text] [Related]

  • 6. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics.
    Watts GF, Chan DC, Somaratne R, Wasserman SM, Scott R, Marcovina SM, Barrett PHR.
    Eur Heart J; 2018 Jul 14; 39(27):2577-2585. PubMed ID: 29566128
    [Abstract] [Full Text] [Related]

  • 7. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study.
    Hollstein T, Vogt A, Grenkowitz T, Stojakovic T, März W, Laufs U, Bölükbasi B, Steinhagen-Thiessen E, Scharnagl H, Kassner U.
    Vascul Pharmacol; 2019 May 14; 116():8-15. PubMed ID: 30910670
    [Abstract] [Full Text] [Related]

  • 8. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus.
    Ooi EM, Watts GF, Chan DC, Pang J, Tenneti VS, Hamilton SJ, McCormick SP, Marcovina SM, Barrett PH.
    Arterioscler Thromb Vasc Biol; 2015 Dec 14; 35(12):2686-93. PubMed ID: 26515419
    [Abstract] [Full Text] [Related]

  • 9. Lipoprotein Metabolism in APOB L343V Familial Hypobetalipoproteinemia.
    Hooper AJ, Heeks L, Robertson K, Champain D, Hua J, Song S, Parhofer KG, Barrett PH, van Bockxmeer FM, Burnett JR.
    J Clin Endocrinol Metab; 2015 Nov 14; 100(11):E1484-90. PubMed ID: 26323024
    [Abstract] [Full Text] [Related]

  • 10. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.
    Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R, Karmally W, Nandakumar R, Fontanez N, Obunike J, Marcovina SM, Lichtenstein AH, Matthan NR, Matta J, Maroccia M, Becue F, Poitiers F, Swanson B, Cowan L, Sasiela WJ, Surks HK, Ginsberg HN.
    Circulation; 2017 Jan 24; 135(4):352-362. PubMed ID: 27986651
    [Abstract] [Full Text] [Related]

  • 11. Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women.
    Wassef H, Bissonnette S, Dufour R, Davignon J, Faraj M.
    J Nutr; 2017 May 24; 147(5):754-762. PubMed ID: 28356429
    [Abstract] [Full Text] [Related]

  • 12. Plasma PCSK9 correlates with apoB-48-containing triglyceride-rich lipoprotein production in men with insulin resistance.
    Drouin-Chartier JP, Tremblay AJ, Hogue JC, Lemelin V, Lamarche B, Couture P.
    J Lipid Res; 2018 Aug 24; 59(8):1501-1509. PubMed ID: 29946054
    [Abstract] [Full Text] [Related]

  • 13. Differences in postprandial concentrations of very-low-density lipoprotein and chylomicron remnants between normotriglyceridemic and hypertriglyceridemic men with and without coronary heart disease.
    Karpe F, Hellénius ML, Hamsten A.
    Metabolism; 1999 Mar 24; 48(3):301-7. PubMed ID: 10094104
    [Abstract] [Full Text] [Related]

  • 14. Composition and distribution of lipoproteins after evolocumab in familial dysbetalipoproteinemia: A randomized controlled trial.
    Heidemann BE, Marais AD, Mulder MT, Visseren FLJ, Roeters van Lennep JE, Stroes ESG, Riksen NP, van Vark-van der Zee LC, Blackhurst DM, Koopal C.
    J Clin Lipidol; 2023 Mar 24; 17(5):666-676. PubMed ID: 37517914
    [Abstract] [Full Text] [Related]

  • 15. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG.
    Diabetes; 2003 Mar 24; 52(3):803-11. PubMed ID: 12606523
    [Abstract] [Full Text] [Related]

  • 16. Decrease in circulating fibroblast growth factor 21 after an oral fat load is related to postprandial triglyceride-rich lipoproteins and liver fat.
    Matikainen N, Taskinen MR, Stennabb S, Lundbom N, Hakkarainen A, Vaaralahti K, Raivio T.
    Eur J Endocrinol; 2012 Mar 24; 166(3):487-92. PubMed ID: 22190000
    [Abstract] [Full Text] [Related]

  • 17. n-3 Polyunsaturated Fatty Acid Supplementation Has No Effect on Postprandial Triglyceride-Rich Lipoprotein Kinetics in Men with Type 2 Diabetes.
    Tremblay AJ, Lamarche B, Hogue JC, Couture P.
    J Diabetes Res; 2016 Mar 24; 2016():2909210. PubMed ID: 27034958
    [Abstract] [Full Text] [Related]

  • 18. Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients.
    Parhofer KG, Laubach E, Barrett PH.
    J Lipid Res; 2003 Jun 24; 44(6):1192-8. PubMed ID: 12671031
    [Abstract] [Full Text] [Related]

  • 19. Postprandial lipoprotein metabolism in familial hypobetalipoproteinemia.
    Hooper AJ, Robertson K, Barrett PH, Parhofer KG, van Bockxmeer FM, Burnett JR.
    J Clin Endocrinol Metab; 2007 Apr 24; 92(4):1474-8. PubMed ID: 17213276
    [Abstract] [Full Text] [Related]

  • 20. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects.
    Parhofer KG, Barrett PH, Schwandt P.
    J Clin Endocrinol Metab; 2000 Nov 24; 85(11):4224-30. PubMed ID: 11095458
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.